Adderall (dextroamphetamine-amphetamine) is a combination of two synthetic agents with central nervous system stimulant activity. Both agents are non-catecholamine, sympathomimetic agents that elevate blood pressure and cause bronchodilation. These agents are commonly abused psychostimulant drugs that induce psychologic dependence manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. Tolerance to various effects develops unequally, so that tachycardia and enhanced alertness diminish while psychotoxic effects (hallucinations and delusions) may occur.
Impax Laboratories, Inc. today announced that it has settled all pending litigation with Shire LLC and Shire Laboratories, Inc. relating to supply of its authorized generic Adderall XR under the parties' License and Distribution Agreement that was signed in January 2006.
Shire plc, today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US.
Continued high use of marijuana by the nation's eighth, 10th and 12th graders combined with a drop in perceptions of its potential harms was revealed in this year's Monitoring the Future survey, an annual survey of eighth, 10th, and 12th-graders conducted by researchers at the University of Michigan.
Today's headlines include previews of how Medicare and other health policy issues might playin tonight's vice presidential debate.
Actavis Group, an international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended-Release Capsules CII, (hereafter referred to as Mixed Amphetamine Salts ER Capsules), in all available strengths: 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg.
On a recent day not far from Capitol Hill and the White House, about a dozen HIV outreach workers toting bright yellow duffle bags stuffed with condoms and prevention information stood outside of the Anacostia Metro station. ... After a couple of hours, they had handed out hundreds of packs of condoms -- and had persuaded 21 people to take an HIV test with an oral swab in a Chevy van parked nearby. "You have to know your status, man. I'd rather be safe than sorry," said Alvern Harris, 25, as he waited for his results.
The public has a famously low opinion of Congress, even though people tend to hold a less disparaging view of their own representatives. The last two years have been especially tough on the institution's reputation, a response to the body's relentless brinkmanship and paralyzing partisanship in the face of a slow economy. So it is with some trepidation that I throw out a little love for a handful of senators still seeking bipartisan agreement on a plan to bring the federal government back to fiscal responsibility.
Pisgah Laboratories, Inc. received Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled "Opioid Salts and Formulations Exhibiting Anti-Abuse and Anti-Dose Dumping Properties."
A shortage of Adderall began last year, sending millions of people with attention deficit/hyperactivity disorder and narcolepsy on perpetual wild goose chases to find drugstores with the pills they need to stay alert and focused. So it's not surprising that Adderall counterfeiters have seized a big marketing opportunity. What is surprising is their clumsiness.
Supernus Pharmaceuticals, Inc. today announced that in December 2011 it closed two transactions through which it raised $42 million.
According to the U.S. Food and Drug Administration (FDA) drugs to treat attention deficit hyperactivity disorder (ADHD) are in such short supply that hundreds of patients complain daily to the agency that they are unable to find a pharmacy with enough pills to fill their prescriptions.
Cigarette and alcohol use by eighth, 10th and 12th-graders are at their lowest point since the Monitoring the Future (MTF) survey began polling teenagers in 1975, according to this year's survey results. However, this positive news is tempered by a slowing rate of decline in teen smoking as well as continued high rates of abuse of other tobacco products, marijuana and prescription drugs.
A new study looked at nearly 150,000 adults taking drugs for attention deficit hyperactivity disorder (ADHD) and found that the medications do not increase the risk for heart attack, stroke, or sudden death from heart-related causes.
Drugs widely prescribed for attention disorders like Ritalin, Adderall and other drugs, did not increase the risk of serious heart problems in a major study published Monday. This could assure parents of children on these medications on heart-related safety of the medicines.
Drugs known as stimulants, that are used to treat attention deficit hyperactivity disorder do not increase the risk of heart attacks, strokes or sudden death, U.S. researchers said on Monday. This study finding should reassure millions of parents whose children take the drugs.
Attention Deficit Hyperactivity Disorder (ADHD) medications do not increase the risk for heart disease or heart attack in children and young adults, according to a Vanderbilt study of 1.2 million patients taking drugs including Ritalin, Adderall, Concerta and Strattera between 1998 and 2005.
The prescribed use of stimulant medications to treat attention deficit hyperactivity disorder (ADHD) rose slowly but steadily from 1996 to 2008, according to a study conducted by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ). The study was published online ahead of print September 28, 2011, in the American Journal of Psychiatry.
Teva Pharmaceutical Industries Ltd. and Alcobra Ltd. announced today top-line results from a six week, randomized, placebo-controlled, Phase II multi-center study designed to assess the safety and efficacy of MG01CI in adults with attention deficit hyperactivity disorder (ADHD).
Shire plc, announces that its subsidiary Shire LLC has filed a lawsuit in the U.S. District Court for the Southern District of New York against Watson Pharmaceuticals, Inc. and its subsidiaries Watson Laboratories, Inc.-Florida, Watson Pharma, Inc., Andrx Corporation, and Andrx Pharmaceuticals, L.L.C. for infringement of Shire's U.S. Reissue Patent No. RE 41,148, U.S. Reissue Patent No. RE 42,096 and U.S. Patent No. 6,913,768 and also for breach of contract.
Supernus Pharmaceuticals, Inc. today announced that its Phase IIa U.S. clinical trial of SPN-812 in adults for the treatment of attention deficit hyperactivity disorder (ADHD) met the primary endpoints of safety and tolerability, and showed statistically significant median reduction versus placebo in both investigator-rated and patient-rated ADHD symptom scores.